SUNPHARMA's weekly performance was disappointing, with a return of -1.48%, indicating a decline in stock value. The stock's volatility was moderate at 18.92%, which is relatively lower compared to its peers. Despite this, SUNPHARMA outperformed its peers DRREDDY and DIVISLAB, but underperformed HINDUNILVR. The stock's Sharpe Ratio of -0.31 and Max Drawdown of -2.26% suggest that it was a relatively risky investment this week.

[Volatility: 18.92%]